Buscar
Ocugen Inc
OCGNAñadir a la lista de seguimiento
1.050USD
+0.030+2.94%
Horarios del mercado 09/14, 12:32（ET）
356.00MCap. mercado
PérdidaP/E TTM
Más Datos de Ocugen Inc Compañía
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Perfil de Ocugen Inc
Símbolo de cotizaciónOCGN
Nombre de la empresaOcugen Inc
Fecha de salida a bolsaDec 03, 2014
Director ejecutivoMusunuri (Shankar)
Número de empleados95
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 03
Dirección11 Great Valley Parkway
CiudadMALVERN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19355
Teléfono14843284701
Sitio Webhttps://ocugen.com/
Símbolo de cotizaciónOCGN
Fecha de salida a bolsaDec 03, 2014
Director ejecutivoMusunuri (Shankar)
Ejecutivos de Ocugen Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.36M
--
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.36M
--
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
214.50K
--
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
214.50K
--
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
1.80K
--
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Uday B. Kompella, Ph.D.
Dr. Uday B. Kompella, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
--
--
Ms. Rita Johnson-Greene
Ms. Rita Johnson-Greene
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Mr. Mohamed Genead, M.D.
Mr. Mohamed Genead, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.36M
--
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.36M
--
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
214.50K
--
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
214.50K
--
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
1.80K
--
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Ocugen Inc?
Los cinco principales accionistas de Ocugen Inc son: Mr. Junge Zhang, Ph.D.
¿Cuántas instituciones poseen acciones de Ocugen Inc (OCGN)?
A fecha de 2026Q1, 276 instituciones poseen acciones de Ocugen Inc, con un valor de mercado combinado de aproximadamente 81.01M, lo que representa el 24.06% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 20937.00.